2
项与 LRPAP1 synthetic long peptide(Erasmus University Medical Center Rotterdam) 相关的临床试验T-cell Epitopes Associated With Impaired Peptide Processing (TEIPP)- Targeting Immunotherapy in Patients With Relapsed Advanced Non Small Cell Lung Cancer (NSCLC)
In this multicenter, open label non-randomized phase I/II dose escalation study with extension cohort HLA-A*0201-positive patients with non small cell lung cancer (NSCLC) can be included. The primary aim of this study is determine the safety, tolerability and immune modulating effects of the therapeutic LRPAP1 synthetic long peptide (LRPAP7-30V-SLP) vaccine (TEIPP24) at different doses. Secondary objectives are to assess the specificity and immune modulatory effects of the vaccine, to assess the antigen and immune status of the patients, and to determine progression free survival (PFS), overall survival (OS), and the radiological tumor response up to one year after first vaccination.
A multicenter, open label non-randomized phase I/II dose escalation studywith extension cohort to determine the safety, tolerability and immunemodulating effects of the therapeutic LRPAP1 synthetic long peptide(LRPAP7-30V-SLP) vaccine (TEIPP24) at different doses in HLA-A*0201-positive patients with non small cell lung cancer (NSCLC).
100 项与 LRPAP1 synthetic long peptide(Erasmus University Medical Center Rotterdam) 相关的临床结果
100 项与 LRPAP1 synthetic long peptide(Erasmus University Medical Center Rotterdam) 相关的转化医学
100 项与 LRPAP1 synthetic long peptide(Erasmus University Medical Center Rotterdam) 相关的专利（医药）
100 项与 LRPAP1 synthetic long peptide(Erasmus University Medical Center Rotterdam) 相关的药物交易
